JAK2-IN-7

• CAT Number: I045439
• CAS Number: 2593402-36-7
• Molecular Formula: C26H33N7O
• Molecular Weight: 459.59
• Purity: ≥95%
• Synonyms: (E)-4-(dimethylamino)-1-[6-[[5-methyl-4-(1-propan-2-ylpyrazol-4-yl)pyrimidin-2-yl]amino]-3,4-dihydro-1H-isoquinolin-2-yl]but-2-en-1-one
• InChI: InChI=1S/C26H33N7O/c1-18(2)33-17-22(15-28-33)25-19(3)14-27-26(30-25)29-23-9-8-21-16-32(12-10-20(21)13-23)24(34)7-6-11-31(4)5/h6-9,13-15,17-18H,10-12,16H2,1-5H3,(H,27,29,30)/b7-6+
• InChIKey: SURRDPSGERGIIM-VOTSOKGWSA-N
• SMILES: CC1=CN=C(N=C1C2=CN(N=C2)C(C)C)NC3=CC4=C(CN(CC4)C(=O)C=CCN(C)C)C=C3

JAK2-IN-7 (Cat No.: I045439) is a potent, selective inhibitor of Janus kinase 2 (JAK2), a tyrosine kinase that mediates signaling for cytokine receptors involved in hematopoiesis, immune regulation, and inflammation. By blocking JAK2 activity, it prevents phosphorylation and activation of STAT transcription factors, reducing downstream gene expression linked to cell proliferation and immune responses. JAK2-IN-7 is used in research to study JAK-STAT pathway biology and to explore therapeutic strategies for myeloproliferative disorders, autoimmune diseases, and inflammatory conditions driven by aberrant JAK2 signaling.

Reference

[1]. Yang T, et al. N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms [published online ahead of print, 2020 Nov 30]. J Med Chem. 2020;10.1021/acs.jmedchem.0c01488.
[Content Brief]